• Home
  • » 
  • Reports
  • » 
  • Bispecific Antibody Therapeutics Market,...

Bispecific Antibodies

Bispecific Antibody Therapeutics Market, 2014 - 2024

  • Lowest Price Guaranteed From USD 1,899

  • Published
    December 2014

  • Pages
    247

  • View Count
    7524

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 4th edition

  1. About 50 different technology platforms have paved the way for the current pipeline of molecules. Triomab (Trion Pharma), BiTE (Amgen), DVD-Ig (AbbVie), Nanobody (Ablynx), DART (MacroGenics) and TandAb (Affimed) are some of the well-known technologies.
  2. Oncology currently dominates the field. About 68% of the industry sponsored molecules are being directed against oncological diseases; with almost two-third of them targeting solid tumors. Non oncological drug indications include rheumatoid arthritis, respiratory diseases and autoimmune diseases.
  3. Drugs are being tested for several indications. This one drug- multiple applications prospect is extremely appealing to drug manufactures as it reduces their development costs and increases chances of creation of drugs for many diseases at once.
  4. Interest of the large and small pharma companies is evident from the fact that about 42 instances of partnership deals have taken place in the last five years (14 in 2014 itself). There are opportunities for the large pharmaceutical companies to either in-license the technology or the product. Companies can develop innovative molecules in-house using in-licensed technology or collaborate on the development of a product already in clinical development to expand their portfolio of drugs.
  5. By 2024, we expect the overall market to be valued at USD 5.8 billion annually. The ongoing evolution of technology platforms and increased venture capital interest will act as strong enablers to support this rapid growth.
  6. Owing to the complexity of the structure of bispecific antibodies, there are abundant opportunities for contract manufacturers in this area. In particular, the purification of bispecific antibodies is a challenging task, making this field attractive for contract manufacturers and purification technology providers.

Report Description

The concept of bispecific antibodies is increasingly gaining traction in the pharma industry owing to several therapeutic advantages and their potential to address challenges known with the monoclonal antibody based therapies. Bispecific antibodies are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

The market is still in its infancy. With the EMA approval for Removab in 2009 and recent filing for blinatumomab, a great deal of interest has been generated in the bispecific antibody market. The pipeline, which is rich and diverse, has drugs being developed for both oncological and non-oncological indications. These drugs are based on about 50 different technological platforms developed by companies such as Trion Pharma, Amgen, AbbVie, Ablynx, Affimed and MacroGenics amongst others. The platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system.

During the course of our research, we came across 37 molecules currently in different stages of clinical development. Over 75% of these molecules are industry sponsored and we expect around 8-9 of them to be launched by the end of this decade, providing the much needed push to this market. In addition to the clinical pipeline, we have identified over 70 molecules which are currently in preclinical / discovery phase. Technological advancements, especially in the purification of bispecific antibodies will ensure the development of products with improved safety, potency and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

 

Scope of the Report

The 2nd edition of the “Bispecific Antibody Therapeutics Market, 2014-2024” report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.

The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. These drugs are being developed for both oncological as well as non-oncological indications. The report highlights various companies which are active in the market and discusses, in detail, the underlying technologies which form the basis of many of the pipeline drugs.

Expecting more FDA and EMA approvals of bispecific antibodies in the coming years, one of the key objectives of this report has been to forecast the bispecific antibody market, currently at a nascent stage, over the course of next ten years. This is done by analysing

  • Molecules in pipeline and drugs approved for marketing across various geographical regions
  • Research programs, focused on bispecific antibody therapeutics, of global pharmaceutical companies and recently established start-ups
  • Technologies to produce bispecific antibodies
  • Development and sales potential based on target consumer segments, expected pricing and the likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs
  • Competitive landscape and inherent threats to growth in the short term and long term

The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of 11 marketed and pipeline bispecific antibodies. Owing to the niche nature of this market, with most products in the pipeline, we have provided three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  presents an executive summary of the report. It offers a high level view on where the bispecific antibody therapeutics market is headed in the mid-long term.

Chapter 3  provides a general introduction to the concept of bispecific antibodies, covering basics such as antibody technology, the conventional monoclonal antibody and its comparison with bispecific antibody. The chapter also highlights the historic evolution of the industry since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.

Chapter 4  provides a detailed overview and background of the bispecific antibodies market. This chapter covers a detailed pipeline analysis of various molecules under preclinical and clinical trials. We have segmented the drugs on the basis of respective technologies and indications.

Chapter 5  analyses the commercial potential of the global bispecific antibody market, with a special emphasis on the future growth over the next ten years. The market forecast is based on the evolution of the current marketed drug (Removab) and the likely adoption of various drugs which are in advanced clinical trial stages.

Chapter 6  focuses on the various technology platforms currently available or being developed for bispecific antibody production. We have profiled, in detail, the most promising technologies which form the basis of upcoming pipeline drugs.

Chapter 7  provides insight to the recent developments in the field of bispecific antibodies. It includes a comprehensive list of partnerships, including the details of agreements, which have taken place between various pharmaceutical companies over the last few years.

Chapter 8  provides profiles of the key companies in the bispecific antibody market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent developments.

Chapter 9  analyses the various factors impacting the global bispecific antibody market under the SWOT framework. We examine the various technological, commercial and regulatory trends which have shaped the industry till date.

Chapter 10  is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends.

Chapter 11  concludes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12  is the appendix, which lists all the companies and organisations mentioned in this report.

Chapter 13  is the appendix, which provides tabulated data and numbers for all the figures provided in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Immunotherapy: Antibody Ammunitions
3.3. Antibody Based Therapeutics
3.3.1. Twelve of the Approved Antibody Based Therapeutics are Non-Canonical
3.3.2. Dominance of Antibody Based Therapeutics
3.4. Structure of an Antibody
3.5. Monoclonal Antibodies v/s. Bispecific Antibodies
3.6. Bispecific Antibody Formats
3.7. Evolution of Bispecific Antibodies
3.7.1. First Generation Bispecific Antibodies
3.7.1.1. Triomabs: Made Using Hybridomas/ Quadromas
3.7.1.2. Shortcoming of First Generation Bispecific Antibodies
3.7.2. Second Generation Bispecific Antibodies
3.7.2.1. Tandem Single-chain Variable Fragment (scFv)
3.7.2.2. Diabodies
3.7.2.3. Two-in-one antibody
3.7.2.4. Dual Variable Domain Antibodies (DVD-Ig)
3.7.2.5. Shortcoming of Recombinant Bispecific Antibodies
3.8. Types of Bispecific Antibodies by Mode of Action
3.8.1. T Cell Engagement
3.8.2. Pre-targeting Systems
3.8.3. Ligand Neutralisation and Cross Linking of Receptors System
3.9. Companies Active in the Market
 
4. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES
4.1. Introduction
4.2. Drugs Indicated for Oncological Diseases
4.3. Drugs Indicated For Non-Oncological Diseases
4.4. Drugs in Preclinical Trials
4.5. Pipeline Analysis
4.5.1. Drugs are Well Distributed in Phase I and Phase II of Clinical Trials
4.5.2. Mechanism Using CD3 Antigen Recognition
4.5.3. Pipeline Dominated by Drugs Indicated for Oncological Diseases
4.5.4. Companies with the Most Active Pipeline
 
5. CURRENT MARKET AND FORECAST
5.1. Introduction
5.1.1. Scope and Limitations
5.1.2. Assumptions for Market Forecast
5.2. Overall Bispecific Antibodies Market
5.2.1. Overall Bispecific Antibodies Market Forecast: Short-Midterm, 2014 -2019
5.2.2. Overall Bispecific Antibodies Market Forecast: Long Term, 2019- 2024
5.3. Evolution of the Bispecific Antibody Market: 2014, 2019 and 2024
 
5.4. Catumaxomab / Removab (Neovii Biotech)
5.4.1. Drug Specifications
5.4.2. Structure and Mechanism of Action
5.4.3. Orphan Drug Designations
5.4.4. Geographical Presence
5.4.5. Cost
5.4.6. Manufacturing
5.4.7. Current Status of Development
5.4.8. Historical Sales (2011 - Q1 2013)
5.4.9. Reimbursement
5.4.10. Market Opportunity in Cancer Associated Malignant Ascites
5.4.11. Catumaxomab / RemovabSales Forecast: Short-Mid Term, 2014 - 2019
5.4.12. Catumaxomab / RemovabSales Forecast: Long Term, 2019 - 2024
 
5.5. Blinatumomab / MT 103/ MEDI 538 / AMG 103 (Amgen / Astellas Pharma)
5.5.1. Drug Specifications
5.5.2. Mechanism of Action
5.5.3. Amgen Driving Further Development
5.5.4. Orphan Drug Designation
5.5.5. Current Development Status
5.5.6. Key Clinical Trial Results
5.5.7. Competitive Landscape
5.5.8. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Short-Mid Term, 2014 - 2019
5.5.9. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Long Term, 2019 - 2024
 
5.6. SAR156597 (Sanofi)
5.6.1. Drug Specifications
5.6.2. Mechanism of Action
5.6.3. Orphan Drug Status
5.6.4. Idiopathic Pulmonary Fibrosis: An Attractive Opportunity
5.6.5. Current Status of Development
5.6.6. SAR156597 Sales Forecast: Short-Mid Term, 2014 - 2019
5.6.7. SAR156597 Sales Forecast: Long Term, 2019 - 2024
 
5.7. MM-111 (Merrimack Pharmaceuticals)
5.7.1. Drug Specifications
5.7.2. Mechanism of Action
5.7.3. Orphan Drug Designation
5.7.4. Manufacturing
5.7.5. Current Development Status
5.7.6. Key Clinical Trial Results
5.7.7. Companion Diagnostic Under Development
5.7.8. MM-111 Sales Forecast: Short-Mid Term, 2014-2019
5.7.9. MM-111 Sales Forecast: Long Term, 2019 - 2024
 
5.8. ACE910 / RG6013 (Chugai, Roche)
5.8.1. Drug Specifications
5.8.2. Mechanism of Action
5.8.3. Current Development Status
5.8.4. Competiton for ACE910
5.8.5. ACE910 / RG6013 Sales Forecast: Short-Mid Term, 2014 - 2019
5.8.6. ACE910 / RG6013 Sales Forecast: Long Term, 2019 – 2024
 
5.9. Duligotumab / MEHD7945A / RG7597 (Roche / Genentech)
5.9.1. Drug Specifications
5.9.2. Structure and Mechanism of Action
5.9.3. Current Status of Development
5.9.4. Key Clinical Trial Results
5.9.5. Competition for Duligotumab
5.9.6. Duligotumab/MEHD7945A / RG7597Sales Forecast: Long Term, 2019 - 2024
 
5.10. ABT-981 (AbbVie)
5.10.1. Drug Specifications
5.10.2. Mechanism of Action
5.10.3. Current Development Status
5.10.4. Key Clinical Trial Results
5.10.5. Competiton for ABT-981
5.10.6. ABT-981 Sales Forecast: Long Term, 2019 – 2024
 
5.11. ABT-122 (AbbVie)
5.11.1. Drug Specifications
5.11.2. Mechanism of Action
5.11.3. Current Development Status
5.11.4. Competition for ABT-122
5.11.5. ABT-122 Sales Forecast: Long Term, 2019 - 2024
 
5.12. RG7221/ RO5520985 (Roche)
5.12.1. Drug Specifications
5.12.2. Mechanism of Action
5.12.3. Current Development Status
5.12.4. Competition for RG7221
5.12.5. RG7221 / RO5520985 Sales Forecast: Long Term, 2019 – 2024
 
5.13. ALX-0061 (Ablynx)
5.13.1. Drug Specifications
5.13.2. Mechanism of Action
5.13.3. Desirable Features of ALX-0061
5.13.4. Current Status of Development
5.13.5. Key Clinical Trial Results
5.13.6. Competiton for ALX-0061
5.13.7. Collaboration with AbbVie
5.13.8. ALX-0061 Sales Forecast: Long Term, 2019 - 2024
 
5.14. Ozoralizumab / ATN-103 (Ablynx)
5.14.1. Drug Specifications
5.14.2. Mechanism of Action
5.14.3. Highs and Lows of Development
5.14.4. CurrentStatus of Development
5.14.5. Key Clinical Trial Results
5.14.6. Competition for Ozoralizumab
5.14.7. Ozoralizumab / ATN-103 Sales Forecast: Long Term, 2019 - 2024
 
5.15. Profiles of Some Other Pipeline Drugs
5.15.1. AFM 13 (Affimed) – Phase II Planned
5.15.1.1. Drug Specifications
5.15.1.2. Mechanism of Action
5.15.1.3. Co-funding Agreement with the Leukemia and Lymphoma Society
5.15.1.4. Current Development Status and Future Plans
5.15.1.5. Competiton for AFM13
5.15.2. CD20Bi / FBT-A05 / Lymphomun (Fresenius Biotech) – investigator-sponsored trials
5.15.2.1. Drug Specifications and Mechanism of Action
5.15.2.2. Current Development Status
5.15.3. TF2 (Immunomedics) – pretargeting imaging and radioimmunotherapy agent
5.15.3.1. Drug Specifications
5.15.3.2. Mechanism of Action
5.15.3.3. Current Development Status
5.15.4. Ertumaxomab/Rexomun (Fresenius Biotech) – investigator-sponsored trials
5.15.4.1. Drug Specifications
5.15.4.2. Current Development Status
 
6. TECHNOLOGY PLATFORMS
6.1. Introduction
6.2. Bispecific Antibody Production: Technology Providers and Available Technologies
6.3. Promising Technologies
 
6.3.1. Triomab / Quadroma (Trion Pharma)
6.3.1.1. The Technology
6.3.1.2. Drugs Based on Triomab
6.3.1.3. Pharmaceutical Companies Showing Interest in the Technology
 
6.3.2. Tribody Technology (Biotecnol)
6.3.2.1. The Technology
6.3.2.2. Drugs Based on Tribody
6.3.2.3. Pharmaceutical Companies Showing Interest in the Technology
6.3.2.4. Advantages of Tribody Technology
 
6.3.3. Bispecific T Cell Engager / BiTE (Amgen)
6.3.3.1. The Technology
6.3.3.2. Drugs Based on BiTE
6.3.3.3. Pharmaceutical Companies Showing Interest in the Technology
6.3.3.4. Advantages of BiTE Technology
 
6.3.4. DART (MacroGenics)
6.3.4.1. The Technology
6.3.4.2. Drugs Based on DART
6.3.4.3. Pharmaceutical Companies Showing Interest in the Technology
6.3.4.4. Advantages of DART
 
6.3.5. DuoBody (Genmab)
6.3.5.1. The Technology
6.3.5.2. Drugs Based on DuoBody
6.3.5.3. Pharmaceutical Companies Showing Interest in the Technology
6.3.5.4. Advantages of DuoBody Technology
 
6.3.6. TandAb (Affimed)
6.3.6.1. The Technology
6.3.6.2. Drugs Based on TandAb
6.3.6.3. Advantages of TandAb Technology
 
6.3.7. DVD-Ig (AbbVie)
6.3.7.1. The Technology
6.3.7.2. Drugs Based on DVD-Ig
6.3.7.3. Advantages of DVD-Ig Technology
 
6.3.8. Nanobody (Ablynx)
6.3.8.1. The Technology
6.3.8.2. Drugs Based on Nanobody
6.3.8.3. Pharmaceutical Companies Showing Interest in the Technology
6.3.8.4. Advantages of Nanobody
 
6.3.9. CrossMab Technology (Roche)
6.3.9.1. The Technology
6.3.9.2. Drugs Based on CrossMab
6.3.9.3. Advantages of CrossMab
 
6.3.10. Dock and Lock (Immunomedics)
6.3.10.1. The Technology
6.3.10.2. Drugs Based on DNL
6.3.10.3. Advantages of DNL Technology
 
7. PARTNERSHIPS: BACKBONE OF THE GROWING BISPECIFIC INDUSTRY
7.1. Chapter Overview
7.2. Recent Partnerships
7.2.1. Partnership Models
7.2.2. Collaborations Amongst Stakeholders are on a Rise
7.2.3. Product Development Model is the Preferred Mode of Collaboration
7.2.4. Most Active Companies
 
8. PROFILES OF LEADING COMPANIES
8.1. Chapter Overview
8.2. AbbVie
8.2.1. Overview
8.2.2. Financial Performance
8.2.3. Technology and PipelineDrugs
8.2.3.1. DVD-Ig: The Proprietary Technology
8.2.3.2. Pipeline Drugs
8.2.4. Other Information
 
8.3. Ablynx
8.3.1. Overview
8.3.2. Financial Performance
8.3.3. Funding
8.3.4. Technology and Pipeline Drugs
8.3.4.1. Nanobody: The Proprietary Technology
8.3.4.2. Pipeline Drugs
8.3.5. Other Information
 
8.4. Affimed
8.4.1. Overview
8.4.2. Funding
8.4.3. Technology and Pipeline Drugs
8.4.3.1. TandAb Technology
8.4.3.2. Pipeline Drugs
8.4.4. Other Information
 
8.5. Amgen
8.5.1. Overview
8.5.2. Financial Performance
8.5.3. Technology and Pipeline Drugs
8.5.3.1. BiTE: The Proprietary Technology
8.5.3.2. Pipeline Drugs
8.5.4. Other Information
 
8.6. Immunomedics
8.6.1. Overview
8.6.2. Financial Performance
8.6.3. Technology and Pipeline Drugs
8.6.3.1. DOCK-AND-LOCK (DNL): The Proprietary Technology
8.6.3.2. Pipeline Drugs
 
8.7. Merrimack Pharmaceuticals
8.7.1. Overview
8.7.2. Financial Performance
8.7.3. Technology and Pipeline Drugs
8.7.4. Other Information
 
8.8. Merus
8.8.1. Overview
8.8.2. Funding
8.8.3. Technology and Pipeline Drugs
8.8.3.1. Biclonics: The Proprietary Technology
8.8.3.2. Pipeline Drugs
8.8.4. Other Information
 
8.9. Neovii Biotech
8.9.1. Overview
8.9.2. Financial Performance
8.9.3. Technologyand Pipeline Drugs
8.9.3.1. Removab: The only Marketed Bispecific Antibody
8.9.4. Other Information
 
8.10. Roche
8.10.1. Overview
8.10.2. Financial Performance
8.10.3. Technology and Pipeline Drugs
8.10.3.1. The Proprietary Technologies
8.10.3.2. Pipeline Drugs
8.10.3.3. Other Information
 
8.11. Sanofi
8.11.1. Overview
8.11.2. Financial Performance
8.11.3. Technology and Pipeline Drugs
8.11.3.1. TBTI (tetravalent bispecific tandem Ig): The Proprietary Technology
8.11.3.2. Pipeline Drugs
 
8.12. Brief Company Profiles
8.12.1. Baliopharm
8.12.2. Bayer
8.12.3. Biotecnol
8.12.4. GSK
8.12.5. MacroGenics
8.12.6. NovImmune
8.12.7. Numab
8.12.8. Paktis Antibody Services GmbH
8.12.9. PharmAbcine
8.12.10. Sorrento Therapeutics
8.12.11. Synimmune
8.12.12. Xencor
8.12.13. Zyngenia
 
9. SWOT ANALYSIS
9.1. Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. INTERVIEW TRANSCRIPTS
 
11. CONCLUSIONS
11.1. A Budding Market Ready to Bloom
11.2. With Several Advantages, Bispecific Antibodies are likely to Step Shead of Competition
11.3. Improvements in Purification Systems of Bispecific Antibodies is Critical
11.4. Concluding Remarks
 
12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS
 
13. APPENDIX 2: TABULATED DATA

List of Figures

Figure 2.1  Bispecific Antibody Therapeutics: Market Map
Figure 3.1  Number of Approved Non-Canonical Antibody Based Therapeutics
Figure 3.2 Sales of Top 10 Drugs (USD BN), 2013
Figure 3.3 Parts of an Antibody
Figure 4.1  Pipeline Drugs: By Phase of Development
Figure 4.2 Pipeline Drugs: By Type of Bispecific System
Figure 4.3 Pipeline Drugs: By Indication
Figure 4.4 Oncology Bispecific Drugs: By Types of Cancer
Figure 5.1 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Base Scenario)
Figure 5.2 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.3  Evolution of Bispecific Antibodies Market: 2014, 2019 and 2024 (Base Scenario)
Figure 5.4  Removab Quarterly Sales, 2011-2013 (EUR MM)
Figure 5.5  Malignant Ascites Market Share (%): Distribution by Type of Cancer
Figure 5.6 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Figure 5.7 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.8 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Figure 5.9 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.10  SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Figure 5.11  SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.12 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Figure 5.13  MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.14 ACE910/ RG6013 Market (USD MM), Short-MId Term Forecast: 2014 - 2019 (Base Scenario)
Figure 5.15  ACE910/ RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.16 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.17 ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.18 ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.19 RG7221/ RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.20 ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 5.21  Sales of Leading Anti-rheumatics Drugs, 2013(USD BN)
Figure 5.22 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Figure 7.1 Bispecific Antibody Partnerships by Year, Pre 2009-2014
Figure 7.2 Bispecific Antibody Partnerships: Distribution by Type of Partnership
Figure 7.3 Bispecific Antibodies Partnerships: Major Stakeholders
Figure 8.1  AbbVie: Financial Performance, 2012 – Q2 2014 (USD BN)
Figure 8.2  Amgen: Financial Performance, 2012 – Q3 2014 (USD BN)
Figure 8.3  Immunomedics: Financial Performance, 2012-2014 (USD MM)
Figure 8.4  Merrimack: Financial Performance, 2012- Q2 2014 (USD MM)
Figure 8.5  Roche: Financial Performance, 2012 – Q3 2014 (CHF BN)
Figure 8.6  Sanofi: Financial Performance, 2012 – Q3 2014 (EUR BN)
Figure 11.1 Bispecific Antibodies Market Forecast (USD MM): 2014, 2019, 2024

List of Tables

Table 3.1  Approved Antibody Based Therapeutics
Table 4.1  List of Bispecific Antibodies: Clinical Trials (Oncology)
Table 4.2  List of Bispecific Antibodies: Clinical Trials (Non-Oncology)
Table 4.3  List of Bispecific Antibodies: Preclinical / Discovery
Table 5.1  Bispecific Antibodies in Clinical Development (Phase II and Higher): Current Development Phase and Expected Launch Year
Table 5.2  Removab: Orphan Drug Designations
Table 5.3  Removab: Treatment Schedule and Cost
Table 5.4  Removab: Ongoing Clinical Trials
Table 5.5  Blinatumomab: Orphan Drug Designations
Table 5.6  Blinatumomab / MT 103/ MEDI 538 / AMG 103: Ongoing Clinical Trials
Table 5.7  Comparison of the Marketed Targeted Inhibitors for ALL
Table 5.8  Comparison of Blinatumomab / MT 103/ MEDI 538 / AMG 103 and SAR3419
Table 5.9  Drugs under Development for Idiopathic Pulmonary Fibrosis, 2014
Table 5.10  SAR156597: Ongoing Clinical Trials
Table 5.11  MM-111: Ongoing Clinical Trials
Table 5.12  ACE910: Ongoing Clinical Trials
Table 5.13  Duligotumab / MEHD7945A / RG7597: Ongoing Clinical Trials
Table 5.14  Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis
Table 5.15  ABT-981: Ongoing Clinical Trials
Table 5.16  ABT-122: Ongoing Clinical Trials
Table 5.17  RG7221: Ongoing Clinical Trials
Table 5.18  ALX-0061: Ongoing Clinical Trials
Table 5.19  ALX-0061: Competitor Drug Analysis
Table 5.20  Ozoralizumab / ATN-103: Ongoing Clinical Trials
Table 5.21  Comparison of Leading Anti-Rheumatic Drugs
Table 5.22  AFM13: Ongoing Clinical Trials
Table 5.23  Comparison of Adcetris with AFM 13
Table 5.24  CD20Bi: Ongoing Clinical Trials
Table 5.25  TF2: Ongoing Clinical Trials
Table 5.26  Rexomun: Ongoing Clinical Trials
Table 6.1  Bispecific Antibodies: List of Technology Platforms
Table 6.2  Drugs Based on Triomab Technology
Table 6.3  Drugs Based on Tribody Technology
Table 6.4  Drugs Based on BiTE Technology
Table 6.5  Drugs Based on DART
Table 6.6  Drugs Based on TandAb Technology
Table 6.7  Drugs Based on DVD-Ig Technology
Table 6.8  Drugs Based on Nanobody Technology
Table 6.9  Drugs Based on CrossMab Technology
Table 6.10  Drugs Based on Dock and Lock Technology
Table 7.1  List of Partnerships, 2000 - 2014
Table 8.1  AbbVie: Pipeline of Bispecific Antibodies
Table 8.2  Ablynx: Pipeline of Bispecific Antibodies
Table 8.3  Affimed: Pipeline of Bispecific Antibodies
Table 8.4  Amgen: Pipeline of Bispecific Antibodies
Table 8.5  Immunomedics: Pipeline of Bispecific Antibodies
Table 8.6  Merrimack Pharmaceuticals: Pipeline of Bispecific Antibodies
Table 8.7  Merus: Pipeline of Bispecific Antibodies
Table 8.8  Neovii Biotech: Pipeline of Bispecific Antibodies
Table 8.9  Roche: Pipeline of Bispecific Antibodies
Table 8.10  Sanofi: Pipeline of Bispecific Antibodies
Table 8.11  Baliopharm: Pipeline of Bispecific Antibodies
Table 8.12  Bayer: Pipeline of Bispecific Antibodies
Table 8.13  Biotecnol: Pipeline of Bispecific Antibodies
Table 8.14  GSK: Pipeline of Bispecific Antibodies
Table 8.15  MacroGenics: Pipeline of Bispecific Antibodies
Table 8.16  NovImmune: Pipeline of Bispecific Antibodies
Table 8.17  Numab: Pipeline of Bispecific Antibodies
Table 8.18  PharmAbcine: Pipeline of Bispecific Antibodies
Table 8.19  Sorrento Therapeutics: Pipeline of Bispecific Antibodies
Table 8.20  Synimmune: Pipeline of Bispecific Antibodies
Table 8.21  Xencor: Pipeline of Bispecific Antibodies
Table 8.22  Zyngenia: Pipeline of Bispecific Antibodies
Table 9.1  SWOT Analysis
Table 9.2  Contract Manufacturing Organisations with Bispecific Antibody Capabilities – Screening, Expression or Purification
Table 9.3  Companies Working to Develop IgG/Non-IgG Fusion Therapeutics
Table 13.1  Approved Non-Canonical Antibody Based Therapeutics
Table 13.2  Sales (USD BN) of Top 10 drugs, 2013
Table 13.3  Industry Sponsored Pipeline Drugs: By Phase of Development
Table 13.4  Industry Sponsored Pipeline Drugs: By Type of Bispecific System
Table 13.5  Industry Sponsored Pipeline Drugs: By Indication
Table 13.6  Industry Sponsored Oncology Bispecific Drugs: By Type of Cancer
Table 13.7  Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Base Scenario)
Table 13.8  Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.9  Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.10  Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.11  Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.12  Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.13  Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Table 13.14  Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.15  Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.16  Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.17  Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.18  Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.19  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Table 13.20  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.21  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.22  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.23  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.24  Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.25  SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Table 13.26  SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.27  SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.28  SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.29  SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.30  SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.31  MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Table 13.32  MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.33  MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.34  MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.35  MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.36  MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.37  ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
Table 13.38  ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
Table 13.39  ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
Table 13.40  ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.41  ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.42  ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.43  Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.44  Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.45  Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.46  ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.47  ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.48  ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.49  ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.50  ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.51  ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.52  RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.53  RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.54  RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.55  ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.56  ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.57  ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.58  Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
Table 13.59  Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
Table 13.60  Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
Table 13.61  AbbVie: Financial Performance, 2012-Q2 2014 (USD BN)
Table 13.62  Amgen: Financial Performance, 2012-Q3 2014 (USD BN)
Table 13.63  Immunomedics: Financial Performance, 2012-2014 (USD MM)
Table 13.64  Merrimack: Financial Performance, 2012- Q2 2014 (USD MM)
Table 13.65  Roche: Financial Performance, 2012-Q3 2014 (CHF BN)
Table 13.66  Sanofi: Financial Performance, 2012-Q3 2014 (EUR BN)

Listed Companies

The following companies have been mentioned in the report.

  1. AbbVie
  2. Abingworth Management
  3. Ablynx
  4. Active Biotech
  5. Adimab
  6. Aeris Capital
  7. Affimed
  8. Aglaia Oncology Seed Fund
  9. Alligator Bioscience
  10. Allozyne
  11. Alta Partners
  12. Ambrx
  13. Amgen
  14. Amphivena Therapeutics Inc
  15. ARIAD Pharmaceuticals
  16. Astellas Pharma
  17. Baliopharm
  18. Bay City Capital
  19. Bayer
  20. Beckman Coulter
  21. Beijing ABT Genetic Engineering Technology Co.
  22. Bicycle Therapeutics
  23. Biogen Idec
  24. Bioloine Rx
  25. BioMedInvest
  26. BioNovion
  27. Biotech Fund Flanders
  28. Biotecnol
  29. BMO Capital Markets Corp.
  30. Boehringer Ingelheim
  31. Bristol-Myers Squibb
  32. Celgene
  33. Cellmid
  34. Celonic AG
  35. Chiome Bioscience
  36. Chromacon
  37. Chugai
  38. Cipla
  39. Cormorant Pharmaceuticals
  40. Covagen
  41. Dow Pharma
  42. Dutalys
  43. Eddingpharm
  44. Eli Lilly
  45. EMD Serono
  46. Emergent Biosolutions
  47. Epigen Biotech
  48. Fabion Pharmaceuticals
  49. FibroGen
  50. Fresenius Biotech
  51. F-star
  52. Fusimab
  53. Ganymed Pharmaceuticals
  54. Genentech
  55. Genmab
  56. Gilead Sciences
  57. GIMV
  58. Glenmark Pharmaceuticals
  59. Glide
  60. Goodwin Biotechnology
  61. GSK
  62. GSK-Domantis
  63. Ho Research Consortium
  64. IBC Pharmaceuticals
  65. ImClone Systems (Eli Lily)
  66. ImmunGene
  67. Immunocore
  68. Immunomedics
  69. Innovent Biologics Inc.
  70. InterMune
  71. J&J
  72. Janssen Biotech
  73. Jefferies LLC
  74. Johnson & Johnson Development Corporation (JJDC)
  75. KBC
  76. KBI Biopharma
  77. Kyowa Hakko Kirin
  78. Leerink Partners LLC
  79. Life Science Partners (LSP)
  80. Lindis Biotech
  81. LSP Life Sciences Partners
  82. MacroGenics
  83. MediaPharma
  84. MedImmune
  85. Merck
  86. Merck Serono
  87. Meridian Life Science
  88. Merrimack Pharmaceuticals
  89. Merus
  90. Micromet
  91. Mitsubishi Tanabe
  92. Molecular Partners AG
  93. MorphoSys AG
  94. MPM Capital
  95. Neovii Biotech
  96. Novartis Option Fund
  97. Novartis Pharmaceuticals
  98. NovImmune
  99. Novo Nordisk A/S
  100. Numab
  101. OcellO
  102. OncoMed
  103. Orbimed
  104. Paktis Antibody Services GmbH
  105. Pfizer
  106. PharmAbcine
  107. Philogen
  108. ProBioGen
  109. Protheragen
  110. Receptor Logic
  111. Renergon Pharmaceuticals
  112. Roche
  113. Sanofi
  114. Sea Lane Biotechnologies
  115. Seattle Genetics
  116. Servier
  117. Shanghai Genomics
  118. Shionogi & Co.
  119. Sofinnova Partners
  120. Sorrento Therapeutics
  121. SR One
  122. Sutro Biopharma
  123. Symphogen
  124. Synergys Biotherapeutics
  125. Synimmune
  126. Takeda
  127. Trion Pharma
  128. Trout Capital LLC
  129. UCB-Celltech
  130. X-BODY Biosciences
  131. Xencor
  132. Zymeworks
  133. ZymoGenetics
  134. Zyngenia

 

 

 

The following organisations have been mentioned in the report.

 

  1. Australian Therapeutic Goods Administration
  2. Barbara Ann Karmanos Cancer Institute
  3. Centre René Gauducheau
  4. Dartmouth-Hitchcock Medical Center
  5. EMA
  6. FDA
  7. French National Centre for Scientific Research
  8. Institut National De La Santé Et De La Recherche Médicale
  9. Krankenhaus Nordwest
  10. Masonic Cancer Center, University of Minnesota
  11. Memorial Sloan-Kettering Cancer Institute
  12. Nantes University Hospital
  13. National Cancer Institute
  14. Radboud University
  15. Roger Williams Medical Centre
  16. Scott and White Hospital
  17. Technische Universität München
  18. Université de Toulouse
  19. University Hospital, Tuebingen

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.